Collegium Pharma (COLL) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 7, 2018 4:01 PM ESTXtampza ER prescriptions grew by 37% in the fourth quarterFDA Approval of sNDA, including Comparative OxyContin Data in labelExpanded product portfolio by licensing rights to commercialize Nucynta franchiseRevenue growth and strong balance sheet provide cash runway into 2020 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.Â
... More